Real life data often highlight side effects of certain drugs not previously reported in randomized controlled trials (RCTs). Objective. To describe cutaneous inflammatory eruptions in psoriatic patients treated with an anti IL-17A agent (secukinumab or ixekizumab). Methods. Retrospective analysis of a cohort of patients with chronic plaque psoriasis who started an anti IL17A agent between September 2016-February 2019 and who developed cutaneous inflammatory eruptions during treatment. A systematic review of similar events reported in the literature was performed. Results. Data of 468 patients were reviewed and 27 cutaneous inflammatory eruptions of 27 patients were collected (prevalence 5.8%). The eruptions appeared after a mean of 16.9

Biologic agents perception in patients attending for the first-time to psoriasis centers. A multicenter Italian survey / Luca, M; Musumeci, Ml; Bardazzi, F; Potenza, C; Bernardini, N; Ferrara, F; Pavone, A; Micali, G.. - In: GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA. - ISSN 1827-1820. - 155:2(2020), pp. 150-154. [10.23736/S0392-0488.17.05754-6]

Biologic agents perception in patients attending for the first-time to psoriasis centers. A multicenter Italian survey

Potenza C;Bernardini N;
2020

Abstract

Real life data often highlight side effects of certain drugs not previously reported in randomized controlled trials (RCTs). Objective. To describe cutaneous inflammatory eruptions in psoriatic patients treated with an anti IL-17A agent (secukinumab or ixekizumab). Methods. Retrospective analysis of a cohort of patients with chronic plaque psoriasis who started an anti IL17A agent between September 2016-February 2019 and who developed cutaneous inflammatory eruptions during treatment. A systematic review of similar events reported in the literature was performed. Results. Data of 468 patients were reviewed and 27 cutaneous inflammatory eruptions of 27 patients were collected (prevalence 5.8%). The eruptions appeared after a mean of 16.9
File allegati a questo prodotto
File Dimensione Formato  
Luca_Biologic-agents_2020.pdf

accesso aperto

Note: https://www.minervamedica.it/it/riviste/Ital-J-Dermatol-Venereol/articolo.php?cod=R23Y2020N02A0150#
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 324.19 kB
Formato Adobe PDF
324.19 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1570804
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact